Skip to main content
OTCMKTS:GNMSF

Genmab A/S Competitors

$372.72
+5.30 (+1.44 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$352.15
$372.80
50-Day Range
$316.28
$381.17
52-Week Range
$278.04
$456.83
Volume174 shs
Average Volume1,207 shs
Market Capitalization$22.99 billion
P/E Ratio5.29
Dividend YieldN/A
Beta0.83

Competitors

Genmab A/S (OTCMKTS:GNMSF) Vs. ZTS, BAYRY, VRTX, REGN, TAK, and ALXN

Should you be buying GNMSF stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Genmab A/S, including Zoetis (ZTS), Bayer Aktiengesellschaft (BAYRY), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TAK), and Alexion Pharmaceuticals (ALXN).

Genmab A/S (OTCMKTS:GNMSF) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares Genmab A/S and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S51.02%34.38%30.65%
Zoetis25.50%63.89%14.99%

Valuation and Earnings

This table compares Genmab A/S and Zoetis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million28.58$324.68 millionN/AN/A
Zoetis$6.26 billion13.00$1.50 billion$3.6447.08

Zoetis has higher revenue and earnings than Genmab A/S.

Volatility and Risk

Genmab A/S has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Genmab A/S shares are held by institutional investors. Comparatively, 92.5% of Zoetis shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Genmab A/S and Zoetis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S00203.00
Zoetis06902.60

Zoetis has a consensus target price of $180.6667, suggesting a potential upside of 4.63%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Genmab A/S.

Summary

Zoetis beats Genmab A/S on 8 of the 13 factors compared between the two stocks.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) and Genmab A/S (OTCMKTS:GNMSF) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Bayer Aktiengesellschaft and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bayer Aktiengesellschaft-22.32%14.23%5.01%
Genmab A/S51.02%34.38%30.65%

Valuation and Earnings

This table compares Bayer Aktiengesellschaft and Genmab A/S's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bayer Aktiengesellschaft$48.23 billion1.34$4.58 billion$1.779.79
Genmab A/S$804.57 million28.58$324.68 millionN/AN/A

Bayer Aktiengesellschaft has higher revenue and earnings than Genmab A/S.

Risk and Volatility

Bayer Aktiengesellschaft has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Insider and Institutional Ownership

0.0% of Genmab A/S shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Bayer Aktiengesellschaft and Genmab A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bayer Aktiengesellschaft09702.44
Genmab A/S00203.00

Summary

Genmab A/S beats Bayer Aktiengesellschaft on 7 of the 11 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Genmab A/S (OTCMKTS:GNMSF) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Vertex Pharmaceuticals and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Genmab A/S51.02%34.38%30.65%

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Genmab A/S's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.50$1.18 billion$4.2950.60
Genmab A/S$804.57 million28.58$324.68 millionN/AN/A

Vertex Pharmaceuticals has higher revenue and earnings than Genmab A/S.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Genmab A/S shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vertex Pharmaceuticals and Genmab A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals041612.86
Genmab A/S00203.00

Vertex Pharmaceuticals currently has a consensus price target of $293.4737, suggesting a potential upside of 34.68%. Given Vertex Pharmaceuticals' higher possible upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Genmab A/S.

Summary

Vertex Pharmaceuticals beats Genmab A/S on 8 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Genmab A/S (OTCMKTS:GNMSF) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Regeneron Pharmaceuticals and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Genmab A/S51.02%34.38%30.65%

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Genmab A/S's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion7.03$2.12 billion$21.4724.03
Genmab A/S$804.57 million28.58$324.68 millionN/AN/A

Regeneron Pharmaceuticals has higher revenue and earnings than Genmab A/S.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Genmab A/S shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Regeneron Pharmaceuticals and Genmab A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051402.74
Genmab A/S00203.00

Regeneron Pharmaceuticals currently has a consensus price target of $656.3810, suggesting a potential upside of 26.96%. Given Regeneron Pharmaceuticals' higher possible upside, equities analysts clearly believe Regeneron Pharmaceuticals is more favorable than Genmab A/S.

Summary

Regeneron Pharmaceuticals beats Genmab A/S on 7 of the 13 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (OTCMKTS:GNMSF) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Insider and Institutional Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 0.0% of Genmab A/S shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Takeda Pharmaceutical and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
Genmab A/S51.02%34.38%30.65%

Analyst Recommendations

This is a summary of current recommendations and price targets for Takeda Pharmaceutical and Genmab A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical02002.00
Genmab A/S00203.00

Valuation and Earnings

This table compares Takeda Pharmaceutical and Genmab A/S's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.79$407.02 million$1.789.62
Genmab A/S$804.57 million28.58$324.68 millionN/AN/A

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S.

Risk and Volatility

Takeda Pharmaceutical has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Summary

Genmab A/S beats Takeda Pharmaceutical on 6 of the 11 factors compared between the two stocks.

Genmab A/S (OTCMKTS:GNMSF) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

0.0% of Genmab A/S shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Genmab A/S and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S51.02%34.38%30.65%
Alexion Pharmaceuticals16.32%23.16%14.76%

Analyst Ratings

This is a summary of current ratings and target prices for Genmab A/S and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S00203.00
Alexion Pharmaceuticals015402.21

Alexion Pharmaceuticals has a consensus target price of $159.3158, suggesting a potential downside of 8.41%. Given Alexion Pharmaceuticals' higher possible upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than Genmab A/S.

Earnings & Valuation

This table compares Genmab A/S and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million28.58$324.68 millionN/AN/A
Alexion Pharmaceuticals$4.99 billion7.68$2.40 billion$9.7417.82

Alexion Pharmaceuticals has higher revenue and earnings than Genmab A/S.

Volatility and Risk

Genmab A/S has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Genmab A/S on 8 of the 13 factors compared between the two stocks.


Genmab A/S Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Zoetis logo
ZTS
Zoetis
1.8$171.36+0.3%$81.11 billion$6.26 billion50.85Analyst Report
Bayer Aktiengesellschaft logo
BAYRY
Bayer Aktiengesellschaft
1.0$17.32+1.0%$64.61 billion$48.23 billion-6.46Earnings Announcement
Analyst Upgrade
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$217.09+1.3%$55.49 billion$4.16 billion27.41
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$516.01+0.2%$55.41 billion$7.86 billion18.86Analyst Report
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$17.12+1.1%$53.46 billion$30.20 billion57.07
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$173.54+0.1%$38.31 billion$4.99 billion40.55
Astellas Pharma logo
ALPMY
Astellas Pharma
1.7$15.26+2.2%$28.41 billion$11.97 billion22.12
BeiGene logo
BGNE
BeiGene
1.3$320.52+3.7%$28.32 billion$428.21 million-15.86Earnings Announcement
Analyst Upgrade
Insider Selling
Shiseido logo
SSDOY
Shiseido
0.9$68.92+1.5%$27.53 billion$10.38 billion-237.66
Takeda Pharmaceutical logo
TKPYY
Takeda Pharmaceutical
1.0$16.94+0.6%$26.47 billion$15.99 billion12.11High Trading Volume
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$40.74+1.4%$24.39 billionN/A0.00Earnings Announcement
Analyst Revision
Genmab A/S logo
GMAB
Genmab A/S
1.4$37.09+1.1%$24.07 billion$804.57 million28.75
MERCK Kommanditgesellschaft auf Aktien logo
MKGAF
MERCK Kommanditgesellschaft auf Aktien
0.5$169.87+4.8%$21.95 billion$18.09 billion0.00Gap Up
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$92.04+4.7%$19.72 billion$1.30 billion25.15Insider Selling
CureVac logo
CVAC
CureVac
0.7$109.92+6.9%$19.13 billionN/A0.00
UCB logo
UCBJF
UCB
1.0$98.00+0.0%$19.06 billion$5.50 billion16.84
Catalent logo
CTLT
Catalent
1.7$102.67+2.1%$17.12 billion$3.09 billion65.39Analyst Revision
News Coverage
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$34.80+2.4%$16.06 billion$3.07 billion-61.05Analyst Upgrade
Insider Buying
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.79+2.1%$15.62 billion$219.75 million-17.34
Zai Lab logo
ZLAB
Zai Lab
1.6$153.16+1.0%$14.36 billion$12.98 million-50.55Earnings Announcement
Analyst Revision
News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.04+2.0%$13.80 billion$1.70 billion17.63Insider Selling
Grifols logo
GRFS
Grifols
1.3$18.72+1.8%$12.64 billion$5.71 billion16.71
OPHLF
Ono Pharmaceutical
1.1$23.80+0.0%$12.24 billion$2.69 billion21.64Upcoming Earnings
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.00+0.8%$12.06 billion$2.32 billion59.50Upcoming Earnings
News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.57+1.4%$11.38 billion$16.89 billion-2.87Insider Selling
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$179.30+0.6%$10.14 billion$2.16 billion56.56Analyst Upgrade
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$29.06+3.1%$10.09 billion$8.60 billion-5.33
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.5$37.95+3.1%$9.47 billionN/A0.00Earnings Announcement
Analyst Report
Lockup Expiration
Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$198.08+2.2%$8.68 billion$1.45 billion18.74Analyst Report
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$156.20+0.9%$7.96 billion$3.34 million-20.29Analyst Revision
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$53.66+5.5%$7.57 billion$40.56 million-15.74Analyst Report
News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$110.93+3.8%$7.20 billion$103.71 million-25.27Analyst Upgrade
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$72.91+6.9%$7.07 billion$87.99 million-86.80
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96+0.0%$6.86 billion$311.33 million-127.30
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$131.96+3.6%$6.84 billion$14.98 million-16.07Upcoming Earnings
Evotec logo
EVTCY
Evotec
0.5$80.50+0.0%$6.62 billion$500.07 million447.25Analyst Upgrade
Perrigo logo
PRGO
Perrigo
2.2$45.86+1.9%$6.01 billion$4.84 billion-764.21Earnings Announcement
Unusual Options Activity
Analyst Revision
News Coverage
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$75.99+4.6%$5.78 billion$380.83 million-9.72
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$96.41+3.7%$5.41 billion$66.51 million17.79
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$38.83+3.8%$5.27 billion$1.12 billion80.90Analyst Report
Allakos logo
ALLK
Allakos
1.7$100.63+2.7%$5.25 billionN/A-36.73Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$76.23+0.2%$4.98 billion$1.00 billion-11.55Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$34.27+0.1%$4.84 billion$150,000.00-16.17Earnings Announcement
Unusual Options Activity
Analyst Revision
I-Mab logo
IMAB
I-Mab
1.0$64.84+4.3%$4.49 billion$4.31 million-2.24Gap Up
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.80+5.4%$4.30 billionN/A-5.69Earnings Announcement
Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.6$61.20+3.6%$4.13 billion$85.54 million0.00Analyst Report
Analyst Revision
News Coverage
Gap Up
LEGN
Legend Biotech
1.3$29.66+4.6%$4.13 billion$64.39 million0.00
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.6$70.74+1.8%$4.06 billion$6.87 million-6.83Gap Up
Hypera logo
HYPMY
Hypera
0.9$6.34+0.8%$4.02 billion$834.89 million14.74
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$25.80+1.3%$3.79 billion$204.89 million-32.25
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.